Literature DB >> 24781714

Collaboration of colorado cancer genetic counselors to integrate next generation sequencing panels into clinical practice.

K Wolfe Schneider1, A Anguiano, L Axell, C Barth, K Crow, M Gilstrap, B A Hamlington, S Lesh, L Mullineaux, A Kulchak Rahm, E Strait, M Freivogel.   

Abstract

The recent introduction of clinically available next generation sequencing (NGS) cancer panels has presented new challenges for genetic counselors. Determining which patients are appropriate for NGS panel testing is complex. Due to the large number of genes included in the NGS panels, thorough and appropriate pre-test counseling and interpretation of NGS results can be a time-consuming and difficult process. Many of the genes associated with increased cancer risk lack published clinical management guidelines and estimates of cancer risk for individuals with deleterious mutations. In order to efficiently and effectively review the clinical utility of NGS panels, Colorado cancer genetic counselors formed a working group to gain a better understanding of the genes included in NGS cancer panels. This publication reports on the approach of this group, the process used to evaluate a selected NGS panel, future directions for this collaboration, and ideas for other genetic counselors to form similar groups to efficiently evaluate new technologies and improve practice.

Entities:  

Mesh:

Year:  2014        PMID: 24781714     DOI: 10.1007/s10897-014-9718-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  12 in total

1.  Ten genes for inherited breast cancer.

Authors:  Tom Walsh; Mary-Claire King
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

2.  A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes.

Authors:  J M Eggington; K R Bowles; K Moyes; S Manley; L Esterling; S Sizemore; E Rosenthal; A Theisen; J Saam; C Arnell; D Pruss; J Bennett; L A Burbidge; B Roa; R J Wenstrup
Journal:  Clin Genet       Date:  2013-12-20       Impact factor: 4.438

3.  Review of massively parallel DNA sequencing technologies.

Authors:  Sowmiya Moorthie; Christopher J Mattocks; Caroline F Wright
Journal:  Hugo J       Date:  2011-10-27

4.  The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Authors:  Marianne Berwick; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Homer Wilcox; Colin B Begg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

5.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

6.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

7.  NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.

Authors:  Janice L Berliner; Angela Musial Fay; Shelly A Cummings; Brittany Burnett; Todd Tillmanns
Journal:  J Genet Couns       Date:  2012-11-28       Impact factor: 2.537

8.  The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.

Authors:  Caitlin B Mauer; Sara M Pirzadeh-Miller; Linda D Robinson; David M Euhus
Journal:  Genet Med       Date:  2013-10-10       Impact factor: 8.822

9.  Mutation screening of RAD51C in male breast cancer patients.

Authors:  Valentina Silvestri; Piera Rizzolo; Mario Falchetti; Ines Zanna; Giovanna Masala; Domenico Palli; Laura Ottini
Journal:  Breast Cancer Res       Date:  2011-02-08       Impact factor: 6.466

10.  Evaluating the utility of personal genomic information.

Authors:  Morris W Foster; John J Mulvihill; Richard R Sharp
Journal:  Genet Med       Date:  2009-08       Impact factor: 8.822

View more
  5 in total

1.  Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Authors:  Kristina G Flores; Laurie E Steffen; Christopher J McLouth; Belinda E Vicuña; Amanda Gammon; Wendy Kohlmann; Lucretia Vigil; Zoneddy R Dayao; Melanie E Royce; Anita Y Kinney
Journal:  J Genet Couns       Date:  2016-08-06       Impact factor: 2.537

2.  Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.

Authors:  Rebecca K Marcus; Jennifer L Geurts; Jessica A Grzybowski; Kiran K Turaga; T Clark Gamblin; Kimberly A Strong; Fabian M Johnston
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

3.  Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome.

Authors:  Carlos J Gallego; Matthew L Perez; Amber Burt; Laura M Amendola; Brian H Shirts; Colin C Pritchard; Fuki M Hisama; Robin L Bennett; David L Veenstra; Gail P Jarvik
Journal:  J Genet Couns       Date:  2015-12-05       Impact factor: 2.537

4.  Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing.

Authors:  Angela R Bradbury; Linda J Patrick-Miller; Brian L Egleston; Laura DiGiovanni; Jamie Brower; Diana Harris; Evelyn M Stevens; Kara N Maxwell; Abha Kulkarni; Tyler Chavez; Amanda Brandt; Jessica M Long; Jacquelyn Powers; Jill E Stopfer; Katherine L Nathanson; Susan M Domchek
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

5.  Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.

Authors:  Angela R Bradbury; Linda Patrick-Miller; Jessica Long; Jacquelyn Powers; Jill Stopfer; Andrea Forman; Christina Rybak; Kristin Mattie; Amanda Brandt; Rachelle Chambers; Wendy K Chung; Jane Churpek; Mary B Daly; Laura Digiovanni; Dana Farengo-Clark; Dominique Fetzer; Pamela Ganschow; Generosa Grana; Cassandra Gulden; Michael Hall; Lynne Kohler; Kara Maxwell; Shana Merrill; Susan Montgomery; Rebecca Mueller; Sarah Nielsen; Olufunmilayo Olopade; Kimberly Rainey; Christina Seelaus; Katherine L Nathanson; Susan M Domchek
Journal:  Genet Med       Date:  2014-10-09       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.